Compare · ABOS vs ARGX
ABOS vs ARGX
Side-by-side comparison of Acumen Pharmaceuticals Inc. (ABOS) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABOS and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 282.2x ABOS ($224.2M).
- ARGX has been more active in the news (11 items in the past 4 weeks vs 5 for ABOS).
- ARGX has more recent analyst coverage (25 ratings vs 12 for ABOS).
- Company
- Acumen Pharmaceuticals Inc.
- argenx SE
- Price
- -
- -
- Market cap
- $224.2M
- $63.27B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2017
- News (4w)
- 5
- 11
- Recent ratings
- 12
- 25
Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ABOS
- SEC Form S-8 filed by Acumen Pharmaceuticals Inc.
- SEC Form 10-Q filed by Acumen Pharmaceuticals Inc.
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
- Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
- Director Porter Derrell exercised 19,500 shares at a strike of $1.07 and sold $75,240 worth of shares (32,300 units at $2.33), decreasing direct ownership by 27% to 35,500 units (SEC Form 4)
- SEC Form 144 filed by Acumen Pharmaceuticals Inc.
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Director Fountain Nathan B sold $14,273 worth of shares (6,400 units at $2.23), decreasing direct ownership by 12% to 48,150 units (SEC Form 4)
- Director Ra Capital Management, L.P. was granted 35,500 shares (SEC Form 4)
Latest ARGX
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE